Moleculin (MBRX) CSO Donald H. Picker Buys Stock

What Happened

• Donald H. Picker, Chief Science Officer of Moleculin Biotech (MBRX), participated in a public offering on August 3, 2026, acquiring 173,333 shares of common stock and Series I warrants to purchase 519,999 additional shares.
• The transaction was structured as units (one share plus three warrants) at a combined purchase price of $0.75 per unit, for total cash paid of approximately $129,999.75 (about $130,000).
• This was a purchase (acquisition), which is generally viewed as a more informative insider action than routine sales.

Key Details

• Transaction date: 2026-08-03; Form 4 filed: 2026-08-05 (timely filing).
• Price/terms: $0.75 per unit (one share + three accompanying Series I warrants). Total cash ≈ $129,999.75.
• Shares acquired: 173,333 common shares (reported as Purchase, code P).
• Derivative acquired: Series I warrants to purchase 519,999 common shares (reported as Derivative).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnote: The filing states the units were acquired in a public offering; warrants are exercisable in the future (series/strike/expiration not detailed in the excerpt).

Context

• The transaction combined a direct equity purchase with attached warrants—effectively buying a package that gives immediate shares plus the right to buy more later if the warrants are exercised.
• Because this is a purchase (not a sale or gift), it indicates the insider committed personal capital to the company, though it does not reveal the insider's motivations or future plans.